Free Trial
→ Why this tiny stock may move before the SpaceX IPO drops (From Behind the Markets) (Ad)tc pixel Free SYRS Stock Alerts

Syros Pharmaceuticals (SYRS) Competitors

Syros Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 06/12/2026 03:45 PM Eastern
Compare

SYRS vs. CARM, ADTX, SCPS, ARDS, and TRVN

Should you buy Syros Pharmaceuticals stock or one of its competitors? MarketBeat compares Syros Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syros Pharmaceuticals include Carisma Therapeutics (CARM), Aditxt (ADTX), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does Syros Pharmaceuticals compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Carisma Therapeutics currently has a consensus price target of $1.00, indicating a potential upside of 16,293.44%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Syros Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Syros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Syros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Syros Pharmaceuticals Neutral

Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

Carisma Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.02-$60.48M$0.730.01
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Carisma Therapeutics beats Syros Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Syros Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Syros Pharmaceuticals N/A -3,369.56%-97.04%

In the previous week, Aditxt had 9 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 9 mentions for Aditxt and 0 mentions for Syros Pharmaceuticals. Aditxt's average media sentiment score of 0.72 beat Syros Pharmaceuticals' score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company Overall Sentiment
Aditxt Positive
Syros Pharmaceuticals Neutral

Aditxt has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AditxtN/AN/A-$41.71M-$100.79 thousandN/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Syros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aditxt has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Summary

Syros Pharmaceuticals beats Aditxt on 7 of the 13 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Scopus BioPharma has higher earnings, but lower revenue than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

In the previous week, Scopus BioPharma had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Syros Pharmaceuticals. Scopus BioPharma's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Syros Pharmaceuticals Neutral

Scopus BioPharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Summary

Scopus BioPharma and Syros Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its share price is 4,397% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Aridis Pharmaceuticals N/A N/A N/A

Aridis Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00

Summary

Aridis Pharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Trevena?

Syros Pharmaceuticals (NASDAQ:SYRS) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Trevena Neutral

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Trevena N/A N/A -119.55%

Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market. Comparatively, Trevena has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Trevena has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Trevena$443K0.00-$40.29M-$47.04N/A

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Syros Pharmaceuticals beats Trevena on 6 of the 10 factors compared between the two stocks.

Get Syros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYRS vs. The Competition

Export
MetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$978.62M$6.74B$12.04B
Dividend YieldN/A4.84%2.67%5.61%
P/E Ratio0.001.4523.9924.44
Price / Sales0.01128.96511.26109.43
Price / CashN/A20.0644.0155.64
Price / Book0.007.8510.656.78
Net Income-$164.57M-$4.88M$3.57B$338.00M
7 Day PerformanceN/A0.31%0.83%2.68%
1 Month PerformanceN/A-0.23%0.08%2.15%
1 Year PerformanceN/A46.36%25.18%30.45%

Syros Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-99.6%$3K$386KN/A120
CARM
Carisma Therapeutics
2.4854 of 5 stars		$0.00
-93.7%		$1.00
+83,233.3%		-98.9%$50K$10.77M0.0020
ADTX
Aditxt
1.015 of 5 stars		$0.03
-42.3%		N/A-100.0%$24KN/AN/A60
SCPS
Scopus BioPharma
N/A$0.00
-33.3%		N/A+33.3%$17KN/AN/A9
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SYRS) was last updated on 6/13/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel